Abbott, the originator of Fragment-Based Drug Discovery, has chosen ZoBio to provide hit discovery and characterization services for Abbott designated targets.
GlaxoSmithKline initially selected ZoBio to provide fragment discovery services for two oncology targets.
Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica NV, has selected ZoBio to provide on going fragment discovery services for targets in a variety of disease areas. The collaboration has been extended to include NMR-based structural studies on target-fragment complexes.
UCB has an ongoing collaboration with ZoBio to provide fragment discovery and characterization services in a variety of disease areas.